Linnaeus Therapeutics is a development-stage biotechnology company engaged in the identification and development of differentiation-based, immunomodulatory small molecule agents for the treatment of numerous cancers.

The company’s compounds also modulate melanocyte pigmentation. They can be used to increase or decrease pigmentation to correct genetic and acquired skin pigmentation conditions as well as aesthetically desirable skin darkening or lightening.

Read More: About Us